What Is Exosome Therapy for Hair Loss?
If you’re looking into non-surgical hair loss treatments, exosome therapy is almost certainly on your list by now. It is one of the more talked-about new options in the UK, which means it comes with a lot of marketing noise and a regulatory picture that is moving quickly.
This is the plain-English version. What exosomes actually are in the context of Hair Loss, what the therapy is trying to do for your hair, what the research does and does not yet show, where it sits in UK regulation, and how we approach it at Hair Revive.
Book your consultation
Exosomes are tiny signalling “parcels” that cells release naturally.
Evidence is early but growing, with multiple studies conducted
Hair Revive uses a salmon-derived E50 preparation, delivered topically
It is best suited to early-to-moderate pattern hair loss where follicles are still living
What Are Exosomes, in Plain English?
Your cells talk to each other all the time. One of the ways they do it is by releasing tiny parcels called exosomes.
Each exosome is a microscopic bubble (around one ten-thousandth the width of a human hair) packed with growth factors, snippets of genetic instructions called microRNA, and other signalling molecules. When one cell releases an exosome and another cell receives it, the receiving cell reads the contents and may respond, by growing, repairing, or behaving differently.
Exosome therapy borrows that natural system. Instead of asking your body to produce the signals, a concentrated preparation of exosomes is applied directly to the area you want to influence. In hair loss, that area is your scalp.
Observing What Already Happens
Exosomes are tiny messengers your cells already use, carrying growth factors and signals that control repair and function across tissues.
We Deliver Those Signals to the Hair
In therapy, these signals are directed specifically at hair follicles, delivering instructions at a cellular level rather than altering hormones or blood flow.
They Reactivate Growth of the Hair
Those signals encourage follicles to stay in the growth (anagen) phase, remain active, and resist the miniaturisation that leads to thinning hair.
The exosomes used clinically are typically produced by specific cell types in a controlled laboratory setting, then purified and concentrated into a sterile preparation ready for use. They carry signalling molecules; they do not contain living cells. That matters both biologically and regulatorily.
The Science of Hair Loss
To understand what exosome therapy is trying to do, it helps to know what is going wrong in most hair loss.
The hair growth cycle
Each hair on your scalp cycles through three phases:
Anagen
"Growth Phase"
The Active Growth Phase typically lasts 2-7 Years on the Scalp
Catagen
"Transition Phase"
Short Transition Phase where Follicle Shrinks
Telogen
"Rest Phase"
Lasts around 3 months before the hair is shed and cycle repeats
Anagen is where the visible length happens, so anything that shortens it tends to show up as thinner, weaker hair over time.
Pattern hair loss and miniaturisation
The most common form of hair loss, androgenetic alopecia, interferes with this cycle.
In genetically susceptible people, a hormone called dihydrotestosterone (DHT) binds to receptors in scalp hair follicles and shortens the anagen phase over time.
The British Association of Dermatologists describes this as miniaturisation: hairs grow back thinner and lighter with each cycle until the follicle eventually stops producing hair altogether. This process lies behind most male and female pattern hair loss.
Over Time the Anagen Phase Gets Shorts and Shorter due to multiple factors, Reducing Growth
First Anagen Phase
Second Anagen Phase
Third Anagen Phase
Other causes
Not all hair loss works the same way. Telogen effluvium pushes a larger-than-normal share of follicles into the rest phase at the same time, producing diffuse shedding a few months after a trigger such as illness, childbirth, surgery or significant stress.
Alopecia areata is an autoimmune condition in which the immune system targets follicles directly. The right treatment pathway depends on which of these is actually behind your case, which is one of the things a proper consultation works out before anything else.
What Exosome Therapy Is Trying to Do
Exosomes are of interest across several of these scenarios because of what they carry.
Mesenchymal stem cell exosomes contain growth factors including vascular endothelial growth factor (VEGF), insulin-like growth factor 1 (IGF-1), and keratinocyte growth factor (KGF).
These are the same signalling molecules that support the dermal papilla, the cluster of cells at the base of the follicle that orchestrates hair growth.
The underlying theory is that delivering these signals directly to the scalp can help extend the anagen phase and support struggling follicles before they miniaturise further.
How It Is Delivered: Injection vs Topical With Microneedling
There are two very different ways exosome therapy can be delivered, and the distinction is both a clinical one and a regulatory one.
Any honest conversation about the treatment should tell you which route a clinic uses.
Injection
Some clinics inject the exosome preparation into the scalp with a fine needle, either just under the skin's surface (intradermal) or a little deeper (subcutaneous).
That is a different procedure, with a different patient experience, and a different place in UK regulation.
Topical Microneedling
The approach we use at Hair Revive is to apply the preparation topically and use microneedling to help it travel down into the scalp. Microneedling creates lots of very small, shallow channels in the skin. Those channels are temporary (your skin closes them up within hours), but while they are open they give the preparation a route towards the follicles.
Is Exosome Hair Restoration Therapy Right For You?
In a world of endless serums, tinctures and procedures it's easy to feel like you're going round in circles.
Exosome Therapy isn't for everybody, and we're upfront about that.
Our 2 Minute Suitability Quiz helps you get a clear picture on whether to proceed with this Treatment or not.
Clinical Evidence and Potential Side Effects
The evidence base for exosome therapy in hair loss is growing but still at an early stage.
The clinical studies completed so far report no serious adverse events attributable to exosome injections, across the small-to-moderate sample sizes reviewed.
A 2025 systematic review published in Clinical, Cosmetic and Investigational Dermatology identified eleven clinical studies on exosome-based treatments for hair regeneration: two randomised controlled trials, three retrospective studies, three prospective single-arm studies, one case series, and two case reports.
All of the studies reported improvements in hair parameters such as density or thickness, and no serious adverse events were noted.
"After 12 months, hair density increased significantly-by +28 ± 4 hairs/cm² in female pattern hair loss (FPHL) and +30 ± 5 hairs/cm² in male pattern hair loss (MPHL) (p<0.05). Patient satisfaction was high, with 80% of participants indicating a good level of satisfaction regarding scalp coverage. Minor adverse events, such as itching, redness, numbness, and headaches, were reported but were not severe."
The scale of the effects reported in those studies is encouraging but should be read with care. Mesenchymal stem cell-derived exosomes in the reviewed studies were associated with hair density increases ranging from around 9.5 to 35 hairs per square centimetre, with most studies showing sustained patient satisfaction during follow-up.
"A statistically significant difference was seen in the answers given in the 12th week compared to the 4th week (p < 0.05).
According to the patients’ answers in the 4th week, a positive change was observed in all but five patients in the 12th week."
A 2024 prospective study in Aesthetic Plastic Surgery followed thirty men with androgenetic alopecia receiving exosome injections and reported improvements in hair density at the one-month and three-month marks.
At the same time, the reviewing authors are explicit about the limits of the current picture. Most studies include small numbers of participants, short follow-up periods, and varied exosome sources and preparations.
The systematic review calls for larger, well-designed clinical trials with extended follow-up to prove efficacy, and for consistent manufacturing standards and regulatory oversight to ensure product safety.
In plain terms: early signals are promising, but exosome therapy has not yet been tested at the scale or under the standardisation that would settle the question.
That is important context to hold alongside any marketing you will see about the treatment. Exosome therapy is an emerging option with a growing evidence base. It is not, on today's evidence, a guaranteed or proven-at-scale intervention in the way that licensed hair loss medicines have been tested over decades.
Our Experience at Hair Revive
We began offering E50 Treatment to our clinic in early 2025.
The pattern we see in practice is broadly consistent with what the wider exosome literature reports: where patients have early-to-mid-stage pattern hair loss and follicles are still present, many go on to see improvements in density and hair condition over the course of treatment.
In cases where follicles are no longer active or the hair loss is advanced, the response is limited, which is why we assess every patient before agreeing a course.
This is clinical observation from practice, not a published audit, and we describe it that way. It informs how we approach patient selection and contributes to our confidence in the protocol. It is not a substitute for peer-reviewed evidence, and we are not presenting it as such.
Clinical Observations at The Hair Revive Clinic
We've proudly offered E50-H Treatment for over a year in our Clinic and tracked our own visitors progress over time.
Visit our Results Page to some of the transformations we've achieved:
VISITOR RESULTS →
Who Exosome Therapy May Help, and Who It May Not
Exosome therapy is most often discussed in the context of androgenetic alopecia, particularly in people in the earlier to mid stages of miniaturisation who still have living follicles on the scalp.
The biological rationale, supported by the early clinical studies, is strongest where there are follicles that can still respond to signalling, rather than areas where they have already shrunk to the point of dormancy.
It may also be considered for people with diffuse thinning caused by telogen effluvium, post-pregnancy shedding, or nutritional and stress-related shedding, where the aim is to support a return to healthier cycling. Some practitioners use it alongside other approaches such as topical minoxidil or PRP, where the objective is a layered approach rather than a single intervention.
| Situation | Suitable? | Why |
|---|---|---|
| Early to mid-stage androgenetic alopecia | Yes | Follicles are still active and responsive |
| Diffuse thinning (telogen effluvium) | Yes | Supports return to healthy hair cycling |
| Post-pregnancy shedding | Yes | Temporary disruption, follicles still viable |
| Stress or nutritional-related shedding | Yes | Temporary disruption, follicles still viable |
| Alongside minoxidil or PRP | Yes | Works well as part of a layered treatment approach |
| Advanced / end-stage pattern baldness | No | Follicles no longer producing; transplant assessment more appropriate |
| Scarring alopecia | No | Follicle permanently destroyed by inflammation or fibrosis |
| Active scalp infection | No | Must be resolved before treatment |
| Uncontrolled psoriasis or eczema (in treatment area) | No | Needs to be managed first |
| Certain underlying medical conditions | Assessment Needed | Requires assessment at consultation |
Exosome therapy is less well matched to certain situations. Advanced, end-stage male or female pattern baldness, where the follicles have stopped producing hair entirely, is not a realistic target for regenerative signalling, and a hair transplant assessment is a more appropriate conversation.
Scarring alopecias, in which the follicle has been destroyed by inflammation or fibrosis, are also unlikely to benefit. Active scalp infections, skin conditions such as uncontrolled psoriasis or eczema in the treatment area, and certain medical conditions make exosome therapy unsuitable until those are addressed.
A responsible consultation should tell you where your specific situation sits on that spectrum. At Hair Revive we would rather tell you that exosome therapy is not the right answer for your case, if that is what we see, than agree to a course that is unlikely to help you.
Safety and Potential Side Effects
The clinical studies completed so far report no serious adverse events attributable to exosome injections, across the small-to-moderate sample sizes reviewed. Side effects reported in practice are typically local and short-lived: mild scalp tenderness, redness, small pinpoint bleeding at injection or microneedle sites, and transient swelling. These generally settle within a day or two.
Because exosome products are biological preparations, the sterility and traceability of the supply matter a great deal. The risks that worry regulators and clinicians are linked to poorly characterised or contaminated products rather than to exosomes themselves as a class. That is why sourcing, storage, and preparation are central questions to ask your clinic, and why treatment under direct medical oversight is the responsible standard.
You should not have exosome therapy if you are pregnant or breastfeeding, if you have an active scalp infection or inflammatory skin condition in the area to be treated, if you have a bleeding disorder or are on anticoagulants without prior clinical review, or if you have certain immune-mediated or oncological conditions that make the risk-benefit balance unsuitable. Your consultation should cover this in detail.
Understanding The Complex Regulatory Picture in the UK and What It Means for You
This is the part of the conversation that most marketing pages skip, and that matters most for your ability to make an informed decision. It is also the part where the specifics matter, because the MHRA's concerns and the UK regulatory framework distinguish between different kinds of exosome treatments in ways that the word "exosome" on its own does not.
In the UK, exosomes are classified by the Medicines and Healthcare Products Regulatory Agency (MHRA) as advanced therapy medicinal products (ATMPs), a regulated category of biological medicines. At the time of writing, no exosome product has been granted a UK marketing authorisation for any therapeutic or aesthetic indication, including hair loss. The overall category is unlicensed, and the evidence base is still developing.
The MHRA has been clear about two specific concerns within that category, and it is worth separating them.
The first is injected exosomes in aesthetic procedures. The MHRA's position is that injecting exosomes, whether intradermally, subcutaneously or intravenously, cannot lawfully be used in aesthetic procedures in the UK, because injected exosomes are treated as medicinal products and no such product holds a UK marketing authorisation for aesthetic use.
The second is human-derived biological material used in cosmetic contexts, which is separately prohibited under UK cosmetics regulation and is the focus of recent investigations into clinics offering treatments using human biological material.
Where Does Hair Revive's Treatment Stand?
With this in mind, note that neither of those specific concerns describes what we do at Hair Revive.
Our E50 exosome preparation is salmon-derived, not human-derived, which means it does not fall within the MHRA's and cosmetics regulator's human-biologicals concern.
Our delivery is topical application combined with microneedling and the TargetCool delivery system, which is not injection. The preparation is placed on the cleansed scalp and carried into the skin through controlled micro-channels.
The treatment is provided under medical oversight in a CQC-registered clinical environment, as a hair loss treatment led by a GMC-registered medical director, rather than as a beauty procedure.
We are not telling you that this means exosome therapy is a licensed or MHRA-approved treatment. It is not, and we would not describe it as such. We are telling you that there is a real difference between the specific practices the MHRA has warned against and the protocol we use, and that this difference is both clinical and regulatory.commit to any course of treatment, and we would rather give it to you up front than after a course of sessions.
Frequently Asked Questions About Exosomes
No exosome product has been granted a UK marketing authorisation for hair loss or any other indication at the time of writing. The MHRA's specific concerns are about injected exosomes in aesthetic procedures and about human-derived biological material in cosmetic contexts.
Our Hair Revive protocol falls outside both: the preparation is salmon-derived, and it is delivered topically with microneedling rather than by injection. Treatment is provided under medical oversight in a CQC-registered clinic led by a GMC-registered medical director.
No. Exosomes are cell-free parcels released by cells, not stem cells themselves. Exosome therapy delivers the signalling molecules exosomes carry, not living cells. That is a different kind of intervention, with a different regulatory classification and different clinical considerations.
Hair follicles respond over months rather than weeks. In the published studies, patients typically report reduced shedding within the first one to two months, with measurable density or thickness changes from three months onwards. Individual response varies, and a responsible clinician will set expectations for your case at consultation rather than quoting generic timelines.
Most patients describe the treatment as well tolerated. There is some scalp sensation during microneedling and mild tenderness afterwards. We use TargetCool to support comfort, and a topical anaesthetic can be used where appropriate.
On the current evidence, exosome therapy is not a realistic option for areas where follicles have already shrunk to dormancy. Regenerative signalling needs living, responsive follicles to work on. If your pattern of loss is advanced in certain areas, a hair transplant conversation is more appropriate, and we will tell you that honestly at consultation.
The clinical studies completed so far report no serious adverse events, and side effects are generally mild, local and short-lived. The safety profile depends heavily on product sourcing, preparation and the qualifications of the treating clinician. Only consider exosome therapy in a CQC-registered medical clinic with GMC-registered clinical oversight and a clearly identified, traceable product.
In many cases, yes. A combined approach is often clinically sensible, because different treatments target different parts of the problem. Your consultation will review any existing medications and plan your treatment around them.
The Best Time To Start Your Hair Restoration Journey? Yesterday.
The second best time? TODAY!
If you're ready to start making meaningful progress towards fuller, thicker hair, then get in touch today.
We are honest and transparent about your potential, and will always set clear expectations, even before you visit us.
So what have you got to lose? Get in touch Today.
Book Online
Call
Text
Visit
Hair Revive at Dr Aesthetica
Unit 1, 1431–1433 Bristol Road South
Birmingham, West Midlands B31 2SU